anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention comprises compounds of the formula:  <FORM:0866433/IV (b)/1> (wherein R1 is hydrogen or halogen and R2 is alkenyl, b -halogeno-ethyl or b -alkoxy-ethyl, the alkoxy group containing at most 4 carbon atoms) and their preparation by reacting salicylamide or a 5-halogeno-salicylamide with an OR2-substituted benzaldehyde. The reaction is preferably effected in an inert solvent, advantageously one which can form an azeotropic mixture with water, when the reaction is carried out at the boiling point of the reaction medium.  Suitable solvents are chloroform, benzene and toluene. Preferably a condensation agent is also present, suitable agents being acids such as sulphuric, phosphoric, benzene-sulphonic and p-toluenesulphonic acids or hydrohalic acids, conveniently in the form of a gas stream in which case a solvent for the hydrogen halide e.g. ethanol, is conveniently also present.  In examples describing the preparation of representative compounds according to the invention R1 is variously hydrogen, chlorine or bromine and R2 is variously allyl, b -chloro-ethyl, b -bromoethyl, b -ethoxyethyl, b -propoxy-ethyl and b -butoxyethyl.ALSO:Pharmaceutical compositions comprise compounds of the formula <FORM:0866433/VI/1> wherein R1 is hydrogen or halogen and R2 is alkenyl, b -halogeno-alkyl or b -alkoxy-ethyl, the alkoxy group containing at most 4 carbon atoms) together with carriers therefor, advantageously in the form of tablets, capsules, suppositories, solutions or emulsions.  The compositions may also contain other active ingredients of antipyretic or antiphlogistic activity, such as caffein or phenacetin, and/or barbiturates.
An "aster" method for injectional correction of the cosmetic defects comprises the subcutaneous administration of the medicamentous product. The point of the maximal invagination of the medial area of the cheek in the area of the atrophy of soft tissues is defined. The medicamentous product is injected into this point with papule technique five times. The first injection is provided in the beginning of nasolabial fold. The following injections are performed circle-wise at the equal distances. The injection points are located at the apices of the regular pentagon.
BACKGROUND: Disparities secondary to underinsurance present throughout the surgical care continuum. Community free clinics are uniquely capable to provide health care services to the medically underserved, but surgery often falls outside their scope of care.
METHODS: Retrospective chart review was conducted on consecutive community free clinic patients receiving free surgical services via referral to a partnering ambulatory surgery center between March 2016 and September 2021. Those with documented contact information were recruited 1-3 years post-procedure for long-term quality-of-life (LTQOL) outcomes assessment via modified Veterans RAND 12-item health survey.
RESULTS: Of 142 included patients, 95.7% identified as Hispanic/Latino and 75.6% were uninsured. Twelve patients had cancerous or precancerous lesions detected and/or removed through diagnostic or definitive procedures. 3.5% experienced postoperative complication including bacterial (n = 2) or fungal (n = 1) surgical site infection and wound dehiscence (n = 2). With a 48.9% response rate, no significant differences in sociodemographic or clinical characteristics were found between surveyed vs non-surveyed patients. Of surveyed patients, 59.7% and 52.2% reported pre-/post-operative improvement in physical health and emotional health, respectively.
DISCUSSION: Free diagnostic screening procedures provided timely diagnoses while free definitive surgeries safely and positively impacted long-term patient-reported physical health. Longitudinal, multidisciplinary follow-up and social support may be warranted to concurrently improve emotional and mental health in similarly underinsured populations.
Particles of a hydrophilic liquid-in-oil emulsion are encapsulated by a process wherein the said emulsion containing an anti-inversion agent in the oil phase is dispersed in an aqueous dispersion of at least two coacervating colloids, at least one of which is gelable and at least one of which is an isoelectric colloid, at a temperature above the gel point of the gelable coacervating colloid and causing a coacervate to deposit on the emulsion particles to form a coating which may subsequently be hardened or plasticized, e.g. by treatment with aqueous formaldehyde.  Conventional thickening agents, e.g. acacia, tragacanth, methyl cellulose, carboxymethylcellulose, magnesium aluminium silicate, polyglycols, glycerin, and syrups may be added to the coacervating medium and to the hydrophilic liquid of the primary emulsion and the latter may also contain conventional emulsifying agents, e.g. esters of polyhydric alcohols, sorbitan- and sorbitan polyoxyethylene derivatives.  The anti-inversion agent may be any material capable of preventing the inversion of the primary emulsion on its dispersion in the coacervating medium, examples being surface-active agents (preferably non-ionic) e.g. sorbitan fatty acid esters and polyoxyethylene sorbitan fatty acid esters, oil-thickening agents, e.g. natural and synthetic waxes, solid fats, sterols and other conventional oil-gelling or oil-thickening agents.  Examples of coacervating colloids are gelatine, albumin, casein, fibrinogen, agar-agar, pectins, collagen, starch acetate phthalate, amylene acetate phthalate (all gellable), alginates, acacia, starch and cellulose acetate phthalate.  Coacervation may be induced by dilution with water of an initial dispersion of the primary emulsion in the coacervating medium or by adjustment of pH. Examples of such processes are given.  Either or both phases of the primary emulsion may contain dissolved or suspended materials which render the capsules of the invention useful as sustained-release fertilizers, plant-growth agents and pesticides, cosmetics, pharmaceuticals with sustained or delayed release for oral, topical or injectable use, additives for incorporation into foodstuffs, e.g. vitamins and ingredients which would normally be lost in a drying step.  Specific examples relate inter alia to encapsulated emulsions comprising: (a) urea in the aqueous phase (fertilizer preparation) and, (b) caffeine in the aqueous phase. Specification 751,600 is referred to.
This invention is a method of killing the stealthy intra-cellular bacteria which are key to the pathogenesis of both Acquired Immune Deficiency Syndrome(s) (AIDS) and Cancers. It is currently believed that the disease(s) known as AIDS are caused by a virus, the Human Immunodeficiency Virus (HIV). But much of the long-term (chronic) destruction of the immune system in AIDS is actually caused by tiny, stealthy, antibiotic-resistant bacteria. The HIV virus weakens the immune system so that the stealthy bacteria can proliferate out-of-control, and the damage of AIDS is done just as much by these bacteria as by any virus. These very tiny L-form Cell-Wall-Deficient (CWD) antibiotic-resistant bacteria live within the cytoplasm of cells, including the phagocytic cells (e.g. monocytes, macrophages, lymphocytes, neutrophils and polymorphonuclear cells) of the immune system itself. The cellular proliferation in Cancer is catalysed the action of the same tiny L-form bacteria. They cause the cell nucleus to release mRNA signaling the Th1 cytokine cascade without the need for conventional signaling via, for example, CD4+ T-Lymphocytes. Some of these Cytokines and Chemokines, including, without limitation, Cellular Adhesion Molecule (CAM), create the environment which allows the cellular proliferation to start, and then allows the cancerous growth to gain a foothold in the body. Killing these stealthy pathogens removes the environment needed to initiate and feed the cellular proliferation commonly called ‘Cancer,’ and prevents the chronic phase of the disease AIDS. This invention achieves its objective partly by reducing the ability of these tiny L-form, intra-phagocytic bacteria to translate proteins within their 70S Ribosome. The 30S and 50S subunits of the bacterial ribosome are targeted both individually and collectively. Further, this invention activates the innate immune system with agonist(s) for the VDR Nuclear Receptor, and modulates the availability of endogenous ligands to the PPAR, GCR and CB1 receptors, conditioning the immune system to more easily recognize and kill these tiny bacterial pathogens.
BACKGROUND: Management of asymptomatic abdominal aortic aneurysm (AAA) based on maximum aneurysm diameter and growth rate fails to preempt many ruptures. Assessment of aortic wall biomechanical properties may improve assessment of progression and rupture risk. This study aimed to assess the accuracy of AAA wall strain measured by cine magnetic resonance imaging (MRI) deformable image registration (MR strain) and investigate its relationship with recent AAA progression.
METHODS: The MR strain accuracy was evaluated in silico against ground truth strain in 54 synthetic MRIs generated from a finite element model simulation of an AAA patient's abdomen for different aortic pulse pressures, tissue motions, signal intensity variations, and image noise. Evaluation included bias with 95% confidence interval (CI) and correlation analysis. Association of MR strain with AAA growth rate was assessed in 25 consecutive patients with >6 months of prior surveillance, for whom cine balanced steady-state free-precession imaging was acquired at the level of the AAA as well as the proximal, normal-caliber aorta. Univariate and multivariate regressions were used to associate growth rate with clinical variables, maximum AAA diameter (D max ), and peak circumferential MR strain through the cardiac cycle. The MR strain interoperator variability was assessed using bias with 95% CI, intraclass correlation coefficient, and coefficient of variation.
RESULTS: In silico experiments revealed an MR strain bias of 0.48% ± 0.42% and a slope of correlation to ground truth strain of 0.963. In vivo, AAA MR strain (1.2% ± 0.6%) was highly reproducible (bias ± 95% CI, 0.03% ± 0.31%; intraclass correlation coefficient, 97.8%; coefficient of variation, 7.14%) and was lower than in the nonaneurysmal aorta (2.4% ± 1.7%). D max ( β = 0.087) and MR strain ( β = -1.563) were both associated with AAA growth rate. The MR strain remained an independent factor associated with growth rate ( β = -0.904) after controlling for D max .
CONCLUSIONS: Deformable image registration analysis can accurately measure the circumferential strain of the AAA wall from standard cine MRI and may offer patient-specific insight regarding AAA progression.
Spinal cord injury (SCI) often leads to neurogenic lower urinary tract dysfunction, causing dysuria and affecting patients' well-being. This study aimed to evaluate the efficacy of a urethral sphincter botulinum toxin A (BoNT-A) injection in patients with SCI and dysuria. This was a retrospective study including 118 patients with SCI who underwent a urethral BoNT-A injection following a standardized protocol for refractory voiding dysfunction. The protocol involved injecting BoNT-A into the urethral sphincter under cystoscopic guidance. Patient demographics, bladder condition parameters, and treatment outcomes were analyzed. Logistic regression and receiver operating characteristic curve analyses were performed to identify predictors of treatment success. Of the 118 patients, 71 (60.1%) showed satisfactory treatment outcomes after the injection. Post-injection status, bladder management, and injection frequency varied significantly among patients with satisfactory and unsatisfactory treatment outcomes. Age, bladder compliance, intravesical pressure, and bladder contractility were indicators of satisfactory outcomes. The first sensation of bladder filling of ≤263 mL, intravesical pressure of ≤28, and bladder contractility index of ≥14 were highly correlated with satisfactory outcomes. A urethral sphincter BoNT-A injection shows promise in managing dysuria in patients with SCI. Understanding bladder condition parameters and patient demographics helps optimize patient selection for this intervention. Further studies are needed to validate these findings and refine treatment protocols.
BACKGROUND: Bacteraemia is a critical condition that generally leads to substantial morbidity and mortality. It is unclear whether delayed antimicrobial therapy (and/or source control) has a prognostic or defervescence effect on patients with source-control-required (ScR) or unrequired (ScU) bacteraemia.
METHODS: The multicenter cohort included treatment-naïve adults with bacteraemia in the emergency department. Clinical information was retrospectively obtained and etiologic pathogens were prospectively restored to accurately determine the time-to-appropriate antibiotic (TtAa). The association between TtAa or time-to-source control (TtSc, for ScR bacteraemia) and 30-day crude mortality or delayed defervescence were respectively studied by adjusting independent determinants of mortality or delayed defervescence, recognised by a logistic regression model.
RESULTS: Of the total 5477 patients, each hour of TtAa delay was associated with an average increase of 0.2% (adjusted odds ratio [AOR], 1.002; P < 0.001) and 0.3% (AOR 1.003; P < 0.001) in mortality rates for patients having ScU (3953 patients) and ScR (1524) bacteraemia, respectively. Notably, these AORs were augmented to 0.4% and 0.5% for critically ill individuals. For patients experiencing ScR bacteraemia, each hour of TtSc delay was significantly associated with an average increase of 0.31% and 0.33% in mortality rates for overall and critically ill individuals, respectively. For febrile patients, each additional hour of TtAa was significantly associated with an average 0.2% and 0.3% increase in the proportion of delayed defervescence for ScU (3085 patients) and ScR (1266) bacteraemia, respectively, and 0.5% and 0.9% for critically ill individuals. For 1266 febrile patients with ScR bacteraemia, each hour of TtSc delay respectively was significantly associated with an average increase of 0.3% and 0.4% in mortality rates for the overall population and those with critical illness.
CONCLUSIONS: Regardless of the need for source control in cases of bacteraemia, there seems to be a significant association between the prompt administration of appropriate antimicrobials and both a favourable prognosis and rapid defervescence, particularly among critically ill patients. For ScR bacteraemia, delayed source control has been identified as a determinant of unfavourable prognosis and delayed defervescence. Moreover, this association with patient survival and the speed of defervescence appears to be augmented among critically ill patients.
Facilitated tucking (FT) is a procedure that kindly flexes the newborn by placing hands on the head and hips. There is no mentioned any risk about this implementation in the literature review. Its effects are that it improves the sleep quality of the newborn and stabilizes the physiological parameters helps to gain a sense of safety related to the position, support the motor development and protect the energy. Studies have shown that facilitated tucking is practiced many times, especially pain management; however, no study has been found examining how it affects stress and comfort of the preterm newborns first nursing care after delivery. Furthermore, vaginal delivery can be a cause of stress alone for all newborns. During these procedures, nursing practices are needed to relieve the stress and to provide comfort on the newborn. Therefore, it is aimed to examine the effect of facilitated tucking after vaginal delivery on late preterm stress, comfort and physiological parameters.

Material and Method: Power analysis for the present study was based on the study by a study which performed the study with at least 32, 30 preterm in each group (with 95% confidence interval and 5% alpha (two tailed)). Herein, the present study was performed with a total of 60 preterm corresponding to 30 preterm for each experimental group (It was assumed that could be lost cases during the study).Randomization was achieved by means of the computer program (https://www.randomizer.org) indicating the total number of preterm, groups and preterm groups and the preterm divided into control and experimental groups.

Experimental group: In order to eliminate the pain and stress that they experience during routine care after vaginal delivery to late preterm. FT implementation begins 3 minutes before the procedures and 10 minutes continuous. After the end of the procedures further 3 minutes was given. Physiological parameters were simultaneously recorded on the registration form. Neonatal Comfort Behavior Scale (NCBS) and Newborn Stress Scale (NSS) were used end of the all procedures which means 13th minute. While FT was implemented by researcher, postpartum care for newborn was performed and recorded by same nurse who is on shift. Evaluation of the scales was evaluated by the researcher and the nurse working in the hospital shift (with 5 years of neonatal experience) (Observer I-Observer II).

Control group: In this group was implemented of the hospital routine care (supine position). Physiological parameters were simultaneously recorded after the vaginal delivery. Neonatal Comfort Behavior Scale (NCBS) and Newborn Stress Scale (NSS) were used end of the all procedures which means 13th minute. Evaluation of the scales was evaluated by the researcher and the nurse working in the hospital shift (with 5 years of neonatal experience) (Observer I-Observer II).
Migrant and seasonal farmworkers are a vulnerable population with a potentially high risk for hearing loss due to farm-related noise exposures. Occupational noise-induced hearing loss (NIHL) is permanent, and it is associated with an increased risk for injuries on the job, as well as communication difficulties, isolation, and depression. The México/US border region is one of the most productive agricultural regions in the country, however, no known studies have explored hearing loss among farmworkers in this area. This pilot study was a first step toward measuring and addressing hearing loss and noise exposure among this region's farmworkers. We conducted a cross-sectional survey to estimate the prevalence of subjective hearing difficulties among Yuma County, Arizona farmworkers. Survey interviews took place during a late-night farmworker health fair from 2 am to 6 am to accommodate local farms' labor schedules. Multivariable regression adjusted for demographic and work covariates estimated subjective hearing loss prevalence ratios. Among 132 farmworker participants, 36% reported they have or might have hearing loss, and 62% reported no hearing loss. Subjective hearing loss prevalence was lower in farmworkers who report not working in noise compared to prevalence in farmworkers who work in noise [prevalence ratio, 0.44 (95% CI 0.23-0.82)]. This report contributes to understanding the perception of hearing-related health and occupational exposures among farmworkers in the México-US Southwest border region. The information from this line of research will inform appropriate safety measures known to lower the risk of experiencing occupational NIHL.
An interactive educational and decision making method and system predominantly pertains to information associated with the diagnosis, treatment, and continued learning that is associated with the innumerable forms of cancer and other diseases. Preferably, a web or mobile application is employed that allows users to quickly and simply understand a variety of highly technical molecular and genetic information pertaining to these cancers, and make calculated medical decisions. Physicians can upload patient specific data to a separate HI&&%%PAA compliant database. Specific patient data can then be used in conjunction with the application to arrive at an effective genomic or biomarker-based treatment. The decision making process may involve at least tumor types, pertinent genes, signaling pathways, targeted drugs, and genetic and other molecular tests. These tools provide information to administer targeted methodologies to treat and diagnose cancer based on genomic data by combining elements of pharmacology, biology, and pathology and laboratory medicine.
From weeks 1-4, participants will consume 150mg daily of a visually identical placebo. For weeks 5-8, the dose will be escalated as participants will consume 300mg daily of placebo supplementation.
Symptomatic hypophosphatemia with serious outcomes including osteomalacia and fractures requiring clinical intervention has been reported in patients treated with Injectafer in the post-marketing setting. These cases have occurred mostly after repeated exposure to Injectafer in patients with no reported history of renal impairment. However, symptomatic hypophosphatemia has been reported after one dose. Possible risk factors for hypophosphatemia include a history of gastrointestinal disorders associated with malabsorption of fat-soluble vitamins or phosphate, inflammatory bowel disease, concurrent or prior use of medications that affect proximal renal tubular function, hyperparathyroidism, vitamin D deficiency, and malnutrition. In most cases, hypophosphatemia resolved within three months.

Correct pre-existing hypophosphatemia prior to initiating therapy with Injectafer. Monitor serum phosphate levels in patients at risk for chronic low serum phosphate. Check serum phosphate levels prior to a repeat course of treatment in patients at risk for low serum phosphate and in any patient who receives a second course of therapy within three months [see Dosage and Administration (2.3)]. Treat hypophosphatemia as medically indicated.
Ubiquitination-mediated protein degradation is integral to plant immunity, with E3 ubiquitin ligases acting as key factors in this process. Here, we report the functions of OsATL32, a plasma membrane-localized Arabidopsis Tóxicos En Levadura (ATL)-type E3 ubiquitin ligase, in rice (Oryza sativa) immunity and its associated regulatory network. We found that the expression of OsATL32 is downregulated in both compatible and incompatible interactions between rice and the rice blast fungus Magnaporthe oryzae. The OsATL32 protein level declines in response to infection by a compatible M. oryzae strain or to chitin treatment. OsATL32 negatively regulates rice resistance to blast and bacterial leaf blight diseases, as well as chitin-triggered immunity. Biochemical and genetic studies revealed that OsATL32 suppresses pathogen-induced reactive oxygen species (ROS) accumulation by mediating ubiquitination and degradation of the ROS-producing OsRac5-OsRbohB module, which enhances rice immunity against M. oryzae. The protein phosphatase PHOSPHATASE AND TENSIN HOMOLOG enhances rice blast resistance by dephosphorylating OsATL32 and promoting its degradation, preventing its negative effect on rice immunity. This study provides insights into the molecular mechanism by which the E3 ligase OsATL32 targets a ROS-producing module to undermine rice immunity.